GlobeNewswire Inc | Sep 9, 2021 07:00AM EDT

September 09, 2021

MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021. The conference will be held from September 13 to September 15, 2021.

An on demand recording of the presentation will be made available on 13 September at 7:00am ET in the Investor Relations section of ASLANs website at www.ir.aslanpharma.com and at the following link: https://journey.ct.events/view/1b10cdbc-a1e0-4f84-b475-753e1832a13a

Media and IR contacts

Emma Thompson Ashley R. RobinsonSpurwing Communications LifeSci Advisors, LLCTel: +65 6206 7350 Tel: +1 (617) 430-7577Email: ASLAN@spurwingcomms.com Email: arr@lifesciadvisors.com

About ASLAN PharmaceuticalsASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLANis currently evaluatingASLAN004, apotential first-in-classantibodytargeting the IL-13 receptor,in atopic dermatitis, and ASLAN003,apotent oralinhibitorofDHODH, which is being developed forautoimmune disease.ASLAN has a team in Menlo Park, California, and in Singapore.For additional information please visitwww.aslanpharma.comor followASLANon LinkedIn.